Mistletoe Therapy / Iscador / Helixor
Mistletoe (Viscum album) lectins (ML-I, ML-II, ML-III) are among the most studied natural anti-cancer compounds with over 100 clinical studies. Lectins induce apoptosis in cancer cells and stimulate NK cells, T-lymphocytes, and macrophages. Subcutaneous Iscador (standardised mistletoe extract) is standard of care integrative adjunct in European oncology (especially Germany), shown to improve quality of life, reduce chemotherapy side effects, and in some studies extend survival. IV mistletoe is now in FDA-approved clinical trials in the USA.
Mechanism of Action
Mistletoe lectins (especially ML-I) bind galactose residues on cancer cell surfaces and trigger apoptosis via caspase activation. Viscotoxins (small proteins) disrupt cancer cell membranes. Mistletoe polysaccharides act as immunomodulators — increasing IL-1, IL-6, TNF-α, and stimulating NK cell cytotoxicity. The combination of direct cytotoxicity and immune stimulation makes it a uniquely multi-modal natural therapy.
Cancer Types Studied
Protocols & Dosing
Subcutaneous Iscador Injections
0.1–10 mg Iscador subcutaneous 3x per week, dose escalated based on response. Use Iscador M (oak mistletoe for male cancers), Iscador P (pine for lung), Iscador Qu (oak for female). Most common European protocol.
IV Mistletoe (Helixor/Iscador IV)
IV mistletoe 30–1000 mg diluted in 250 ml saline over 1–2 hours, 1–3x per week. Under oncologist supervision. FDA approved for clinical trials in USA.
Combination with Conventional Treatment
Mistletoe most effective as adjunct alongside chemotherapy/radiation. Given 1–2 days apart from chemotherapy infusion. Reduces neutropenia, nausea, fatigue.
NIH / PubMed Research
Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.
Cautions & Contraindications
- Use only standardised pharmaceutical preparations (Iscador, Helixor, Eurixor) — raw plant is toxic
- May cause mild fever, local injection site reactions, flu-like symptoms (signs of immune activation)
- Avoid in leukaemia and lymphoma without specialist guidance — immune stimulation may be counterproductive
- Contraindicated in autoimmune conditions
- IV mistletoe should be administered by physician — allergic reactions possible
- Avoid within 48 hours of checkpoint inhibitor immunotherapy
Informational only. Not medical advice. Consult your oncologist before starting any alternative or integrative therapy.